Towards a paradigm shift in the treatment of chronic Chagas disease. - Wikidata - thesis-toulmin - TriplyDB

Towards a paradigm shift in the treatment of chronic Chagas disease.

Towards a paradigm shift in the treatment of chronic Chagas disease.

http://www.wikidata.org/entity/Q37544885

about

Course of Chronic Trypanosoma cruzi Infection after Treatment Based on Parasitological and Serological Tests: A Systematic Review of Follow-Up Studies Revisiting the Posttherapeutic Cure Criterion in Chagas Disease: Time for New Methods, More Questions, Doubts, and Polemics or Time to Change Old Concepts?4-Aminopyridyl-Based CYP51 Inhibitors as Anti- Trypanosoma cruzi Drug Leads with Improved Pharmacokinetic Profile and in Vivo Potency Safety Profile of Nifurtimox for Treatment of Chagas Disease in the United States High throughput screening for anti-Trypanosoma cruzi drug discovery Evaluation of Parasiticide Treatment with Benznidazol in the Electrocardiographic, Clinical, and Serological Evolution of Chagas Disease A family cluster of Chagas disease detected through selective screening of blood donors: A case report and brief review Proteasome inhibition for treatment of leishmaniasis, Chagas disease and sleeping sickness Positive deviance study to inform a Chagas disease control program in southern Ecuador Rapid diagnostic tests duo as alternative to conventional serological assays for conclusive Chagas disease diagnosis.Chagas disease and the london declaration on neglected tropical diseases.Drug strategies targeting CYP51 in neglected tropical diseases Arthritis and benznidazole: more closely related than we thought.Eco-bio-social research on community-based approaches for Chagas disease vector control in Latin America Experimental benznidazole treatment of Trypanosoma cruzi II strains isolated from children of the Jequitinhonha Valley, Minas Gerais, Brazil, with Chagas disease.Rapid and sensitive ultra-high-pressure liquid chromatography method for quantification of antichagasic benznidazole in plasma: application in a preclinical pharmacokinetic study.Differential phenotypic and functional profiles of TcCA-2 -specific cytotoxic CD8+ T cells in the asymptomatic versus cardiac phase in Chagasic patients.Population pharmacokinetics of benznidazole in adult patients with Chagas disease.Target Product Profile (TPP) for Chagas Disease Point-of-Care Diagnosis and Assessment of Response to Treatment.Integrated control of Chagas disease for its elimination as public health problem--a review Electrocardiographic Abnormalities and Treatment with Benznidazole among Children with Chronic Infection by Trypanosoma cruzi: A Retrospective Cohort Study Comprehensive Survey of Domiciliary Triatomine Species Capable of Transmitting Chagas Disease in Southern Ecuador.Prevalence of Chagas Disease in a U.S. Population of Latin American Immigrants with Conduction Abnormalities on Electrocardiogram."I Cannot Be Worried": Living with Chagas Disease in Tropical Bolivia.Improving access to Chagas disease diagnosis and etiologic treatment in remote rural communities of the Argentine Chaco through strengthened primary health care and broad social participation Risk factors associated with Chagas disease in pregnant women in Santander, a highly endemic Colombian area.New Scheme of Intermittent Benznidazole Administration in Patients Chronically Infected with Trypanosoma cruzi: a Pilot Short-Term Follow-Up Study with Adult Patients Benznidazole Extended-Release Tablets for Improved Treatment of Chagas Disease: Preclinical Pharmacokinetic Study.Developments in the management of Chagas cardiomyopathy.Serological based monitoring of a cohort of patients with chronic Chagas disease treated with benznidazole in a highly endemic area of northern Argentina Potential new clinical therapies for Chagas disease.Recent clinical trials for the etiological treatment of chronic chagas disease: advances, challenges and perspectives.Gene-deleted live-attenuated Trypanosoma cruzi parasites as vaccines to protect against Chagas disease.Nanomedicines against Chagas disease: an update on therapeutics, prophylaxis and diagnosis.Autoimmune pathogenesis of Chagas heart disease: looking back, looking ahead.A strategy for scaling up access to comprehensive care in adults with Chagas disease in endemic countries: The Bolivian Chagas Platform.Novel drug discovery for Chagas disease.Long-term comparative pharmacovigilance of orally transmitted Chagas disease: first report.A 12-mer repetitive antigenic epitope from Trypanosoma cruzi is a potential marker of therapeutic efficacy in chronic Chagas' disease.Benznidazole therapy for Chagas disease in asymptomatic Trypanosoma cruzi -seropositive former blood donors: evaluation of the efficacy of different treatment regimens.

P2860

Q26782118-B0FE275C-A8A8-4F8C-A61E-1E0460B7D532 Q26859040-AC12AB38-0575-48D1-81F6-A59BE059C18D Q27684956-DBBEB7B8-7466-4EC1-B504-F593131FFA90 Q28277238-CB0D79D8-DCAA-4CA9-A679-5058992AE081 Q28542489-AD10E8D1-67DD-4909-B5D6-373A4611471A Q28550722-61A6680B-6B1A-47FF-9E8B-88625C83C65D Q28646790-DFE5D89A-1250-41FD-8FAD-299B94397673 Q28817181-DC61361D-E2A9-46EF-948E-C8CB61618612 Q30388244-DFF37F71-151C-4498-A279-76B35921B1E6 Q33563137-EE815911-F1E6-4DFB-A3E8-40BEC2A94672 Q34315066-75369A11-3CC9-4F5D-9034-E2823F6B988D Q34622554-FAA1F3DE-F5FB-4F26-B720-83A8272D813E Q34923301-428894BB-F9BA-43D4-B08A-183CB1078AC2 Q34986702-D23EB92A-F59E-4EB2-8A77-0C686CEE0F47 Q35210866-0F7DA3BD-EF84-4018-9D81-D66A9D2A00F0 Q35450419-3465C4ED-5EE3-4BB5-89DC-967A0BDDCEE3 Q35588670-396D8752-999E-450C-9A37-79909D296920 Q35607812-EF3ECCE8-1354-48EF-B121-D001BCE76411 Q35652603-C44D76B6-5FAD-42B0-A6BF-703826B73F25 Q35810731-8C139FEB-45A7-4E95-9CB6-101EEB5E9207 Q36012043-3E5DC5DB-5C14-401D-A001-0DD5FB00D1FF Q36127535-78E1E11D-0535-46FB-A782-42AB48BBFB72 Q36240224-B0E32E7B-D6D7-4992-AF52-66E07FE50998 Q36252752-F0A8AF44-8C55-4AD2-A379-FC9D781C8179 Q36278397-2D5F83FD-54B4-4B5C-A41B-3171EC70334B Q36533047-CA919617-E8DC-4D7A-A3B8-2A6DDE8F4354 Q36571807-91652A0F-35EB-49E5-AF09-35A2DC0CD684 Q36729990-580A47AC-7F24-4C21-9300-2DB8EB827E3B Q36737035-46A33BBC-6E93-4A0A-BE1D-C525851E9E80 Q37007518-5A7F7C48-FC05-44F9-9C70-3E8BD8127BC7 Q38203330-A5E3991A-6CCE-4D30-B25A-0CA0349B3CB5 Q38256874-FE62C1B0-7F8F-481E-8EAC-B56739622064 Q38286350-5BCC4843-BFE3-4B89-AB65-141CFB3A057C Q38364470-DF37255A-4899-48FD-8CA2-117549ABE91D Q38412987-A6FE37C6-F39C-49E3-80FE-01816CD537F3 Q38640312-1B16ECC5-0E41-4BFD-A4AF-CBC079742A0C Q38770142-0846E9B5-12E7-410A-A3C8-71E85FF2F9A6 Q38867072-0BC5E857-E0A9-4F97-889D-45D4CDF9C23D Q39002789-09F5AABB-C424-4A87-AA0D-1A178842FEFE Q39078120-547F8324-81A4-4DCD-ACF5-CDC8A670338E

P2860

Towards a paradigm shift in the treatment of chronic Chagas disease.

http://www.wikidata.org/entity/Q37544885

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh

2013年學術文章

@zh-hant

name

Towards a paradigm shift in the treatment of chronic Chagas disease.

@en

Towards a paradigm shift in the treatment of chronic Chagas disease.

@nl

type

label

Towards a paradigm shift in the treatment of chronic Chagas disease.

@en

Towards a paradigm shift in the treatment of chronic Chagas disease.

@nl

prefLabel

Towards a paradigm shift in the treatment of chronic Chagas disease.

@en

Towards a paradigm shift in the treatment of chronic Chagas disease.

@nl

P1433

Q37544885-6F5E14D5-F8C6-4EF8-BA91-A66D7D79DE5B

P1476

Q37544885-DABB80DE-B108-4B18-A0F8-EB0516DFF22C

P2093

Q37544885-1863E110-8F5F-4F1E-9045-95E8C6A21D22

Q37544885-1FDEE4F5-FF8A-47B3-917D-39217E0A8B34

Q37544885-2F71BE5E-D55C-4CFD-87E6-38B0331E0FD2

Q37544885-75AC4CF9-CA54-4E62-B24A-1BF765FB3298

Q37544885-94840444-FBC0-4306-AC5B-16C38D9A3C88

Q37544885-9EBE77DF-C41A-4744-A381-F21E8DF042A4

Q37544885-AF895813-0FF8-40FE-8249-976028A7C8CB

Q37544885-BE3A833A-1CEF-4D26-B125-6052FB8F676A

Q37544885-F15E1523-704C-4311-AB8C-62400B1AC95A

P2860

Q37544885-0805D8FE-335E-4879-BB5C-D867220025E8

Q37544885-1170A038-336B-4DF6-8F66-1E29688C1A27

Q37544885-14AA084B-81BC-4DE3-B7AD-D136F3C2B017

Q37544885-16D1AB0C-BB95-4D0D-89D7-27D9173D66F4

Q37544885-19F136C7-BFE0-4003-809E-C68F118F7501

Q37544885-1DAA40E1-B97D-483D-A4E9-20C8146F6601

Q37544885-26AAA3A4-57FB-4284-9EC8-30AE1B6C600D

Q37544885-30013F39-B293-46E6-B37E-C4128FF508DA

Q37544885-367A1252-8E90-4CB2-BE08-9661096AF23E

Q37544885-3AA46AA1-21E4-47C4-AF45-06AAC3CA43A1

P304

Q37544885-10ED65E8-245A-49AA-A85F-B743DE4C7820

P31

Q37544885-3C67C012-5F7B-4A95-AAC6-B6A5CAA7937C

P356

Q37544885-64BEA7B6-C7A5-40DD-BA20-759A04E76571

P407

Q37544885-AC28E15B-4EA7-4E4A-A77D-01E0FB07CE17

P433

Q37544885-DFCFC8F3-82D3-4B73-9474-FB39D78BD808

P478

Q37544885-13B5C0CD-DB84-453E-8CD6-4DEBB1F08EE9

P50

Q37544885-10D74823-686D-4849-A84D-CC8488BA96AF

Q37544885-67E1F11E-04AA-47B4-B090-84DE7D9FE53A

Q37544885-74B2EEBE-13D0-414C-839C-8C3AF299094F

Q37544885-BB5EBD38-842C-4DE6-A32A-C7E016A4F132

P577

Q37544885-45012259-D0A8-4B1C-8F7A-A18899C9FD29

P698

Q37544885-0247524E-35DC-4FB0-96BA-0A6C0EBCBDFD

P921

Q37544885-5EFBE5F7-CDA6-4C91-AE54-C02E1812273F

P932

Q37544885-882C6627-2E51-4945-9C81-5192123DC02D

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

Towards a paradigm shift in the treatment of chronic Chagas disease

@en

P2093

A G Schijman

http://www.w3.org/2001/XMLSchema#string

B Alarcón de Noya

http://www.w3.org/2001/XMLSchema#string

F Torrico

http://www.w3.org/2001/XMLSchema#string

I Ribeiro

http://www.w3.org/2001/XMLSchema#string

J M Ramsey

http://www.w3.org/2001/XMLSchema#string

Latin American Network for Chagas Disease, NHEPACHA

http://www.w3.org/2001/XMLSchema#string

R Viotti

http://www.w3.org/2001/XMLSchema#string

S Sosa-Estani

http://www.w3.org/2001/XMLSchema#string

T Araujo-Jorge

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations

Pathogenesis of chronic Chagas heart disease

Feasibility, drug safety, and effectiveness of etiological treatment programs for Chagas disease in Honduras, Guatemala, and Bolivia: 10-year experience of Médecins Sans Frontières

Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy.

Chagas' disease and the autoimmunity hypothesis.

Coronary microvascular disease in chronic Chagas cardiomyopathy including an overview on history, pathology, and other proposed pathogenic mechanisms.

International study to evaluate PCR methods for detection of Trypanosoma cruzi DNA in blood samples from Chagas disease patients.

Immunopathology of Chagas disease.

Short-term follow-up of chagasic patients after benzonidazole treatment using multiple serological markers.

Impact of aetiological treatment on conventional and multiplex serology in chronic Chagas disease.

P304

635-639

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.01662-13

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

58

http://www.w3.org/2001/XMLSchema#string

P50

Joaquim Gascón

Mario J. Grijalva

P577

2013-11-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24247135

http://www.w3.org/2001/XMLSchema#string

P921

P932

3910900

http://www.w3.org/2001/XMLSchema#string